Aspen the drug firm has proposed an £8m settlement with the Competition and Markets Authority (CMA) following an investigation into the supply of life saving treatment on the NHS.
The CMA said Aspen agreed the payment as part of a wider package following the probe into the suspected anti competitive arrangements over the supply of fludrocortisone acetate 0.1mg tablets.
Aspen had paid two rivals to stay out of the market and the CMA said they suspected competition law had been broken.
CMA chief executive Andrea Coscelli said, “We consider it unacceptable for the NHS, and the taxpayers who fund it to have to pay millions of pounds more than they should for this life-saving drug.”
He added, “The £8m Aspen has agreed to provide will save the NHS the time and expense of seeking damages in court.
“Importantly, Aspen has also committed to ensuring there are more competitors in this market, giving the NHS the opportunity to secure better value for UK taxpayers’ money in the future.”